^
    Back
    Association details:
    Biomarker:MDM2 amplification
    Cancer:Sarcoma
    Drug:milademetan (RAIN-32) (MDM2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Milademetan in Advanced/Metastatic Solid Tumors

    Excerpt:
    ...- MDM2 amplification:...
    Trial ID:
    MANTRA-2
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2021
    Title:

    1521O - A phase II biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, an ultra-rare cancer with highly life-threatening unmet medical needs (NCCH1806/MK004)

    Published date:
    09/13/2021
    Excerpt:
    Of the ten evaluable patients, two had partial responses. Response rate and disease control rate were 20% (95% CI 2.5-55.6) and 50% (95% CI 18.7-81.3), respectively....Milademetan showed acceptable safety profile with some clinical activity in patients with intimal sarcoma with MDM2 amplification.